Description
Bortezomib belongs to a class of anti-cancer medicine, which is in the form of lyophilized powder A first beneficial proteasome inhibitor is known as
Bortezomib proteasome is a cellular structure which breaks the proteins.
Important points
Bortezomib should be used alone or combined with dexamethasone Three-week course is considered as therapy cycle A minimum 72 hours should slip away between constant doses of Bortezomib.
Key points
Partially, 72 hours should be passing between following doses of
Bortezomib.
Dosage & Administration
Bortezomib (lyophilized powder form) is reconstituted by using 0.9% sodium chloride (NS) Bortezomib should be reconstituted in 3.5ml NS The route of administration is IV bolus Intrathecal not use for administration.
In adults:
Mantle cell lymphoma
The
Bortezomib recommended dose for untreated mantle cell lymphoma is; 1.3mg/m2 of Bortezomib administered as IV bolus given as two times weekly by combining with rituximab, cyclophosphamide, doxorubicin, and tablet prednisolone for two weeks (day I, IV, VIII & XI) followed rest period of 10 days (day II through 21).
In Relapse stage
The usual dose of
Bortezomib is 1.3mg/m2 should be administered through IV bolus or subcutaneous as two times for two weeks (day1, 4, 8, and 11) followed by a ten day rest course (day 12 through 21) Treatment schedule increased above 8 cycles may be taken once weekly for 4 weeks (day 1, 8, 15, and 22), followed by 13 day rest (day 23 over 35)
Mechanism of action :
Pharmacological category: anti-neoplastic agent or proteasome inhibitor
Bortezomib is a type of chymotrypsin-like activity unpredictable inhibitor of the 26S proteasome in human cells. The 26S proteasome is a big protein multiplex which degraded the accompany proteins The functioning site of proteasome has Chymotrypsin like Trypsin like Postglutamyl peptide hydrolysis activity The 26S proteasome enzyme recede assorted proteins which demanding to tumor cells survival like cyclins, tumor suppressors, BCL-2 & cyclin-dependent kinase inhibitors Prevention of these degenerations, sensitizes cells to apoptosis and cell arrest.
Side effects
Black tarry stools, Bleeding gums, Blood in urine, Blurred vision, Body aches, Burning, crawling, itching, numbness, prickling, Chest pain.
Storage
Bortezomib vial should be stored at 20°C to 25°C (68°F to 77°F) excursion between 15°C to 30°C (59°F to 86°F) Keep away from light and heat.
Missed Dose
If the patient fails to take the dose of
Bortezomib, must consult with a medical oncologist and followed the dosing schedules. Do not self-administered.
FOR MORE INFORMATION:
EMAIL:
applepharmaceutical@gmail.com
No comments:
Post a Comment